首页> 外文期刊>Journal of tissue engineering and regenerative medicine >Is percutaneous injection of bone marrow concentrate, demineralized bone matrix and PRF an alternative to curettage and bone grafting for treating aneurysmal bone cyst?
【24h】

Is percutaneous injection of bone marrow concentrate, demineralized bone matrix and PRF an alternative to curettage and bone grafting for treating aneurysmal bone cyst?

机译:经皮骨髓浓缩物,脱矿质骨基质和PRF是治疗动脉瘤囊肿的替代品的替代品曲线和骨嫁接吗?

获取原文
获取原文并翻译 | 示例
           

摘要

To determine the efficacy and safety of a single injection with autologous bone marrow concentrate (BMC) combined with demineralized bone matrix (DBM) and platelet-rich fibrin (PRF) compared to curettage and bone grafting for treating aneurysmal bone cysts (ABC). Two hundred thirty-nine patients were treated with curettage and bone grafting (Curettage Group), and 21 with percutaneous injection of DBM associated with autologous BMC and PRF (DBM + BMC + PRF Group). All patients attended the outpatient clinic to assess ABC healing and clinical results at the first 3, 6, 9 and 18 months after surgery and then annually in the absence of symptoms. The mean follow-up was 42 months for the Curettage Group (range 6-180 months) and 28 months for the DBM + BMC + PRF Group (range, 6-85 months). Out of the 21 patients who had injection with BMC, DBM, and PRF, 17 (80%) require no additional treatment and they were considered healed. Of the 239 patients treated with curettage and bone grafting after core needle or open biopsy, 177 (74%) were considered healed after the first treatment. Injection in comparison with curettage presented the same risk for local recurrence. The overall rate of local recurrence for all patients was 25%. Univariate and multivariate analyses showed a significant difference in local recurrence rates in patients younger than 15 years, and for the cyst located in the long bones of the lower limbs than the cyst located in the long bones of the upper limbs.
机译:研究自体骨髓浓缩物(BMC)、脱矿骨基质(DBM)和富含血小板的纤维蛋白(PRF)单次注射治疗动脉瘤性骨囊肿(ABC)的疗效和安全性,并与刮除术和植骨术进行比较。299例患者接受刮除和植骨治疗(刮除组),21例患者接受经皮注射DBM联合自体BMC和PRF治疗(DBM+BMC+PRF组)。所有患者在术后的前3、6、9和18个月,以及在没有症状的情况下,每年都到门诊评估ABC愈合和临床结果。刮除组平均随访42个月(范围6-180个月),DBM+BMC+PRF组平均随访28个月(范围6-85个月)。在注射BMC、DBM和PRF的21名患者中,17名(80%)不需要额外治疗,他们被认为已痊愈。在239名患者中,有177名(74%)患者在第一次治疗后被认为已痊愈,他们在核心针或开放式活检后接受了刮宫和植骨治疗。注射与刮宫相比,局部复发的风险相同。所有患者的局部复发率为25%。单变量和多变量分析显示,15岁以下患者的局部复发率存在显著差异,位于下肢长骨的囊肿的局部复发率高于位于上肢长骨的囊肿。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号